Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Comment by ohbehaveon Jun 19, 2019 9:02pm
63 Views
Post# 29842255

RE:RE:RE:Very illiquid

RE:RE:RE:Very illiquidAs Maxmoe stated .. all the info is on SEDAR and there's also a new corprate presentation on their website but yes the company is headquartered in AB and based on the new presentation current production is 900boepd consisting of 40% liquids of which >200bopd were just added from the new REX well so the impact of this discovery appears to be material. They advise there are 18 "follow up opportunities" in this pool and that they have lands tied up on two analog pools identified from vertical well logs which are untested with HZ drilling. Corporate upside seems to be there and the new well plus the two farmout wells planned for this year at zero cost should significantly improve the cash flow. 

Share ownership is listed as follows:

Ownership

Management and Directors15.0%
Evenergy Company Limited*15.3%
Institutions – est.14.6%
Retail – est.55.1%

*Evenergy is a subsidiary of Zhongcheng Group, one of the largest privately owned petroleum, oil products and LPG distribution and retail companies in China
<< Previous
Bullboard Posts
Next >>